New drug approved for the treatment of blood cancer in India, know which stage patients will benefit?
Mumbai. There is relief news for patients with blood cancer in India. Actually, a new drug has been approved for these cancer patients. Recently, Bangalore-based Biotech Startup Immuneal Therapeutics launched a CAR-T cell therapy, Qartemi, a CAR-T cell therapy, a CAR-T cell therapy for patients with B-cell non-Hozkin lymphoma.
Read:- Satpal Sharma elected unopposed president of BJP Jammu and Kashmir unit, know the new chief's political journey
This will be beneficial for serious blood cancer patients and the victims who have reached the relapsed stage. According to Emunil, this drug is the second CAR-T cell therapy approved in India, before the Central Drug Standards Control Organization (CDSCO) approved the domestic NexCAR 19, which has been developed by Immunoct, which has been developed by the Indian Institute of Technology Bombay (IITV) And Tata is an incubated company at Memorial Hospital.
What is Living Drug?
According to the information, Qartemi is a living drug, let us know that the living medicine is made entirely of functional cells. Those who are chosen to treat cancer and are often modified. Explain that it is different from traditional chemical medicine. Due to being made of cells, they have long immune response.
How does Car-t cell therapy work?
This new drug works with cell therapy, which is extracted from the patient and then revised and then inserted back into the patient. In scientific language it is called car-t cell therapy which is a type of immunotherapy. In this therapy, the patient's T cells are genetically used to attack cancer cells.
Comments are closed.